Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
Angiogenesis is a key process in cancer development. We performed a meta-analysis to assess the efficacy and safety of the novel VEGFR-2 inhibitors in patients with metastatic gastric and gastroesophageal junction cancer. A literature-based meta-analysis of randomized controlled trials (RCTs) was undertaken. The primary outcome was the overall survival. The pooled analysis from RCTs on anti-VEGFR-2 inhibitors revealed a significant increase in overall survival (hazard ratio for death: 0.69, 95% confidence interval: 0.55-0.87; p = .002). This study confirms the efficacy of novel anti-VEGFR-2 inhibitors. The future studies of these agents will evaluate alone and in combination with chemotherapy the early line of treatment along with the identification of proper predictive biomarker.
a Department of Oncology , Medical Oncology Unit, San Donato Hospital , Arezzo , Italy.|b Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona , Cremona , Italy.|c Department of Medical , Surgery and Health Sciences, University of Trieste , Trieste , Italy.
Giandomenico
G
Roviello
d Unit of General and Minimally Invasive Surgery, Surgery and Neuroscience ; University of Siena , Siena , Italy.
Karol
K
Polom
d Unit of General and Minimally Invasive Surgery, Surgery and Neuroscience ; University of Siena , Siena , Italy.
Franco
F
Roviello
d Unit of General and Minimally Invasive Surgery, Surgery and Neuroscience ; University of Siena , Siena , Italy.
Daniele
D
Marrelli
e Medical Oncology Unit , University of Siena , Siena , Italy.
Andrea Giovanni
AG
Multari
f Unit of General Medicine , AziendaOspedaliera "C. Poma" Presidio Ospedaliero di Pieve di Coriano , Mantova , Italy.
Giovanni
G
Paganini
g Unit of Radiotherapy, Department of Medical , Surgical Sciences and Neurosciences, Siena University , Siena , Italy.
Chiara
C
Pacifico
b Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona , Cremona , Italy.|c Department of Medical , Surgery and Health Sciences, University of Trieste , Trieste , Italy.
Daniele
D
Generali
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018572:Disease-Free Survival; D004943:Esophagogastric Junction / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D016016:Proportional Hazards Models; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*; D000096662:Ramucirumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011725:Pyridines; D040301:Vascular Endothelial Growth Factor Receptor-2; D000096662:Ramucirumab; C553458:apatinib; C000588866:KDR protein, human
VEGFR-2; angiogenesis; apatinib; ramucirumab